<?xml version="1.0" encoding="UTF-8"?><xml><records><record><source-app name="Biblio" version="7.x">Drupal-Biblio</source-app><ref-type>17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Psichogiou, M</style></author><author><style face="normal" font="default" size="100%">Karabinis, A.</style></author><author><style face="normal" font="default" size="100%">Pavlopoulou, I D</style></author><author><style face="normal" font="default" size="100%">Basoulis, D.</style></author><author><style face="normal" font="default" size="100%">Petsios, K.</style></author><author><style face="normal" font="default" size="100%">Roussos, S.</style></author><author><style face="normal" font="default" size="100%">Pratikaki, M.</style></author><author><style face="normal" font="default" size="100%">Jahaj, E.</style></author><author><style face="normal" font="default" size="100%">Protopapas, K</style></author><author><style face="normal" font="default" size="100%">Leontis, K.</style></author><author><style face="normal" font="default" size="100%">Rapti, V.</style></author><author><style face="normal" font="default" size="100%">Kotanidou, A.</style></author><author><style face="normal" font="default" size="100%">Antoniadou, A</style></author><author><style face="normal" font="default" size="100%">Poulakou, G</style></author><author><style face="normal" font="default" size="100%">Paraskevis, D</style></author><author><style face="normal" font="default" size="100%">Sypsa, V</style></author><author><style face="normal" font="default" size="100%">Hatzakis, A</style></author></authors></contributors><titles><title><style face="normal" font="default" size="100%">Antibodies against SARS-CoV-2 among health care workers in a country with low burden of COVID-19</style></title><secondary-title><style face="normal" font="default" size="100%">PLoS OnePLoS OnePLoS One</style></secondary-title><alt-title><style face="normal" font="default" size="100%">PloS one</style></alt-title><short-title><style face="normal" font="default" size="100%">PloS onePloS one</style></short-title></titles><keywords><keyword><style  face="normal" font="default" size="100%">Adolescent</style></keyword><keyword><style  face="normal" font="default" size="100%">Adult</style></keyword><keyword><style  face="normal" font="default" size="100%">Aged</style></keyword><keyword><style  face="normal" font="default" size="100%">COVID-19 Serological Testing/*statistics &amp; numerical data</style></keyword><keyword><style  face="normal" font="default" size="100%">COVID-19/diagnosis/*epidemiology</style></keyword><keyword><style  face="normal" font="default" size="100%">Female</style></keyword><keyword><style  face="normal" font="default" size="100%">Greece/epidemiology</style></keyword><keyword><style  face="normal" font="default" size="100%">Health Personnel/*statistics &amp; numerical data</style></keyword><keyword><style  face="normal" font="default" size="100%">Humans</style></keyword><keyword><style  face="normal" font="default" size="100%">Male</style></keyword><keyword><style  face="normal" font="default" size="100%">Middle Aged</style></keyword></keywords><dates><year><style  face="normal" font="default" size="100%">2020</style></year></dates><number><style face="normal" font="default" size="100%">12</style></number><edition><style face="normal" font="default" size="100%">2020/12/04</style></edition><volume><style face="normal" font="default" size="100%">15</style></volume><pages><style face="normal" font="default" size="100%">e0243025</style></pages><isbn><style face="normal" font="default" size="100%">1932-6203</style></isbn><language><style face="normal" font="default" size="100%">eng</style></language><abstract><style face="normal" font="default" size="100%">INTRODUCTION: Greece is a country with limited spread of SARS-CoV-2 and cumulative infection attack rate of 0.12% (95% CI 0.06-0.26). Health care workers (HCWs) are a well-recognized risk group for COVID-19. The study aimed to estimate the seroprevalence of antibodies to SARS-CoV-2 in a nosocomial setting and assess potential risk factors. METHODS: HCWs from two hospitals participated in the study. Hospital-1 was a tertiary university affiliated center, involved in the care of COVID-19 patients while hospital-2 was a tertiary specialized cardiac surgery center not involved in the care of these patients. A validated, CE, rapid, IgM/IgG antibody point-of-care test was used. Comparative performance with a reference globally available assay was assessed. RESULTS: 1,495 individuals consented to participate (response rate 77%). The anti-SARS-CoV-2 weighted prevalence was 1.26% (95% CI 0.43, 3.26) overall and 0.53% (95% CI 0.06, 2.78) and 2.70% (95% CI 0.57, 9.19) in hospital-1 and hospital-2, respectively although the study was underpowered to detect statistically significant differences. The overall, hospital-1, and hospital-2 seroprevalence was 10, 4 and 22 times higher than the estimated infection attack rate in general population, respectively. Suboptimal use of personal protective equipment was noted in both hospitals. CONCLUSIONS: These data have implications for the preparedness of a second wave of COVID-19 epidemic, given the low burden of SARS-CoV-2 infection rate, in concordance with national projections.</style></abstract><accession-num><style face="normal" font="default" size="100%">33270691</style></accession-num><notes><style face="normal" font="default" size="100%">1932-6203Psichogiou, MinaOrcid: 0000-0002-3000-8447Karabinis, AndreasPavlopoulou, Ioanna DOrcid: 0000-0003-0607-8266Basoulis, DimitriosOrcid: 0000-0002-0686-872xPetsios, KonstantinosRoussos, SotiriosOrcid: 0000-0003-2347-0817Pratikaki, MariaJahaj, EdisonProtopapas, KonstantinosLeontis, KonstantinosRapti, VasilikiKotanidou, AnastasiaAntoniadou, AnastasiaPoulakou, GaryphalliaParaskevis, DimitriosOrcid: 0000-0001-6167-7152Sypsa, VanaHatzakis, AngelosJournal ArticleResearch Support, Non-U.S. Gov'tPLoS One. 2020 Dec 3;15(12):e0243025. doi: 10.1371/journal.pone.0243025. eCollection 2020.</style></notes><custom2><style face="normal" font="default" size="100%">PMC7714091 interest for the primary investigator, HA due to the funding received from Gilead. No other participant in the study has received funds from Gilead in any form or has been employed by Gilead. No participants have received funds for consultation services or donations or worked for any commercial company that would constitute a conflict of interest for the authors, including but not limited to Abbott and GenBody. The aforementioned competing interest does not alter our adherence to PLOS ONE policies on sharing data and materials.</style></custom2><auth-address><style face="normal" font="default" size="100%">First Department of Internal Medicine, Laiko General Hospital, Medical School, National and Kapodistrian University of Athens, Athens, Greece.Onassis Cardiac Surgery Center, Athens, Greece.Pediatric Research Laboratory, Faculty of Nursing, National and Kapodistrian University of Athens, Athens, Greece.Clinical Research Office, Onassis Cardiac Surgery Center, Athens, Greece.Department of Hygiene, Epidemiology and Medical Statistics, Medical School, National and Kapodistrian University of Athens, Athens, Greece.1st Department of Critical Care &amp; Pulmonary Services, Medical School, National and Kapodistrian University of Athens, Evangelismos Hospital, Athens, Greece.4th Department of Internal Medicine, Medical School, National and Kapodistrian University of Athens, Athens, Greece.3rd Department of Internal Medicine, Sotiria General Hospital, Medical School, National and Kapodistrian University of Athens, Athens, Greece.</style></auth-address><remote-database-provider><style face="normal" font="default" size="100%">NLM</style></remote-database-provider></record></records></xml>